Infectious Dis. Medical News about Tuberculosis, Pulmonary

Become a Member Today!
Register

Most Viewed Abstracts

1. Report Shows Shift in Starting Salaries for Physicians

2. Use of Antiemetic Agents in Acute Gastroenteritis

3. 2008 Exclusive Survey—Earnings: Good news for primary care income

4. Medicare pay-for-reporting effort draws fire from frustrated doctors

5. Debunking Myths in the US Healthcare System

Your Article Summary

See Latest Articles

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Opportunist mycobacterial lung disease – which drug combination is more effective
Breathe, 09/29/09

Over the three species combined, different therapeutic regimens (REClari and RECipro), did not differ meaningfully in terms of deaths due to mycobacteria, failures of treatment, relapses and deaths due to all causes. Immunotherapy with four doses of M. vaccae over the first 6 months did not improve the outcome. Immunotherapy with M. vaccae has not fulfi lled expectations when used in the treatment of tuberculosis. The same disappointing result has now been demonstrated in the treatment of pulmonary disease caused by opportunist myocobacteria. As these diseases appear to be markers of poor health, optimising general health, managing comorbidity in this population and research for better antimycobacterial drugs are needed urgently.

<< Previous
Burkholderia cepacia Complex: Impact on the Cystic Fibrosis Lung...

Next >>
NK cells protect secondary lymphoid tissue from cytomegalovirus...